Antibodies against TIM3 and uses thereof

US12129297B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Xiao Min Schebye · Palomar Park, US
• Mark J. Selby · San Francisco, US
• Michelle Minhua HAN · Piedmont, US
• Christine Bee · San Francisco, US
• Andy X. Deng · Princeton, US
• Anan Chuntharapai · Daly City, US
• Brigitte Devaux · Palo Alto, US
• Huiming LI · Lexington, US
• Paul O. Sheppard · Granite Falls, US
• Alan J. Korman · Piedmont, US
• Daniel F. ARDOUREL · Woodinville, US
• Ekaterina Deyanova · Lawrenceville, US
• Richard Y. Huang · Princeton, US
• Guodong Chen · East Brunswick Township, US
• Michelle Kuhne · San Francisco, US
• Hong-An TRUONG · San Francisco, US

Key dates

• Filing date: Jan 11, 2019
• Grant date: Oct 29, 2024
• Expiry date: Jan 8, 2040

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/70503
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are antibodies, or antigen binding portions thereof, that bind to T-cell immunoglobulin and mucin-domain containing-3 (TIM3) protein. Also provided are uses of these antibodies, or antigen binding portions thereof, in therapeutic applications, such as treatment of cancer. Further provided are cells that produce the antibodies, or antigen binding portions thereof, polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof, and vectors comprising the polynucleotides encoding the heavy and/or light chain regions of the antibodies, or antigen binding portions thereof.